CompletedPhase 3

Gardasil Versus Cervarix in the Treatment of Warts

Egypt50 participantsStarted 2020-09-01

Plain-language summary

Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or immunotherapeutic. Human papilloma virus (HPV) vaccines are FDA approved for the prevention of genital warts and wart related precancerous and cancerous lesions but they are not indicated for treatment of preexisting warts yet

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult Patients with recalcitrant multiple warts of any type. Warts were considered recalcitrant if they persisted for at least 6 months without any response to 2 different therapeutic modalities or more. * Immunocompetent patients. * Patients who do not receive any treatment of warts for at least 1 month before the start of study. * Patients who are able to understand and follow the study protocol and approve to sign the informed consent Exclusion Criteria: * Patients with acute febrile illness. * Past history of asthma. * Allergic skin disorders, such as generalized eczema, or severe urticaria. * Pregnancy or lactation * History of hypersensitivity to the treatment vaccines. * Children * Immunocompromised patients * Patients unable to follow the study protocol

What they're measuring

Therapeutic response

Timeframe: Through study completion for a maximum of 12 weeks, evaluation held at two weeks interval and at the end of treatment sessions (12th week visit)

Trial details

NCT IDNCT05383625

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2021-10-01

View on ClinicalTrials.gov More Verruca Viral trials